TMPRSS2-ERG fusion can block XRCC4-mediated NHEJ by inhibiting DNA-PKcs auto/trans-phosphorylation and thus sensitizes prostate cancer cells to PARP inhibition [86]. The gene discussed is ERG; the disease is Familial prostate cancer.